OSE Immunotherapy receives FDA orphan status for VEL-101

French biotech OSE Immunotherapy received FDA orphan status for VEL-101 in preventing heart transplant rejection.

Published 11sem1 sourceMajorupdated 11sem

≈ 18sSpeed

The fact

This status accelerates regulatory review and opens commercial opportunities in a niche market.

VEL-101 is a first-in-class monoclonal antibody agonist targeting FPR2.

Click the link to read an article on the topic:

Explore this topic

Accélération de la commercialisation de VEL-101 sur le marché américain des greffes

Réduction des délais de développement clinique grâce au processus orphelin

Auto-synthesis from 1 media source · identified on April 28, 2026